BioNxt Moves R&D to Munich's Gen-Plus CRDO for Drug Delivery Innovations

BioNxt Solutions Inc, a bioscience firm focused on cutting-edge drug delivery systems, is thrilled to share a significant achievement in its research and development progress. The firm is moving its innovative R&D tasks to the Gen-Plus Contract Research and Development Organization (CRDO) located in Munich, Germany, with operations set to start on March 1, 2025. This action highlights BioNxt’s dedication to scientific advancement and developing solutions for unaddressed medical requirements.

The newly established laboratory offers BioNxt access to state-of-the-art technologies, an enlarged 1,000-square-meter research space, and strategic prospects for scientific collaboration in Europe’s biotech center. The shift is anticipated to speed up the company's current initiatives, especially concerning drug delivery systems, therapies for neurodegenerative diseases, and advanced biomedical technologies.

Utilizing the cutting-edge infrastructure of the Gen-Plus Laboratory, BioNxt intends to take advantage of the facility’s 1,000 square meters of modern space tailored for high-potency active pharmaceutical ingredients and processes that comply with GMP standards.

“BioNxt’s transition to Gen-Plus marks a pivotal moment for BioNxt,” said  Hugh Rogers, CEO of BioNxt Solutions Inc. “This transition is both strategic and timely, and unlocking new possibilities for added strength on IP with innovation and reinforcing our mission to deliver transformative therapies for patients worldwide. We are thrilled about the opportunities that this new chapter brings, providing Impact on Current and Future projects”